周一，H.C. Wainwright重申了对Pliant Therapeutics (NASDAQ:PLRX)股票的买入评级，目标价维持在$38.00。该公司的乐观态度源于bexotegrast治疗特发性肺纤维化(IPF)的BEACON-IPF临床试验的进展。该试验正按计划进行，预计患者招募将在2025年第一季度结束。 BEACON-IPF试验是一项为期52周的研究，旨在评估bexotegrast ...

自从2011年IPF诊疗指南发布，经过大量的临床试验吡非尼酮和尼达尼布被美国FDA批准上市，应用于IPF的治疗中。这2种药物对于轻到中度肺功能损害的IPF患者能起到改善肺功能的下降、延缓疾病进程的目的，同时也提出早期诊断和早期治疗的重要性。

The primary focus is on the company’s bexotegrast, an αvß6/αvß1 integrin inhibitor, which is being developed for the treatment of idiopathic pulmonary fibrosis (IPF). The enrollment for the Phase 2b/3 ...

The winner of the Established Business to Business category in The Australian Financial Review Customer Champions list 2024, ...

Panagiotis Tarinidis has unofficially exceeded the U66KG IPF Raw Total World Record with a score of 713 kilograms (1,571.9 ...

随着人工智能等技术的不断创新，其在医疗领域的应用加速落地。其中，将人工智能应用于药物研发中的探索正在加快步伐。Nature数据显示，一款新药的研发成本平均约26亿美元，耗时10年，成功率不到10%。不过，人工智能有望应用于药物研发中的多个场景和阶段，帮助提高新药研发的效率和成功率。业内专家指出，AI制药行业发展已 ...

Living with IPF is never dull, says columnist Sam Kirton, who shares some updates on topics he's discussed in recent columns.

IPF severely impacts quality of life, limiting daily activities due to progressive respiratory decline. Median survival for IPF patients is approximately 3 to 5 years post-diagnosis. The financial ...

周五，Stifel重申了对Pliant Therapeutics (NASDAQ:PLRX)股票的买入评级，目标价保持在32.00美元。该投资公司的前景仍然乐观，因为Pliant Therapeutics正在推进其Bexotegrast治疗特发性肺纤维化(IPF)的2/3期BEACON-IPF试验。IPF是一种以肺部瘢痕形成为特征的疾病，目前亟需有效的治疗方法。 预计该试验的2b期部分将在2025 ...

The Association of Real Estate Funds (AREF), the British Property Federation (BPF) and the Investment Property Forum (IPF) ...

A recent study showed that the COPD assessment test was reliable and responsive for assessing health status in fibrotic ...